Navigation Links
Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents
Date:7/7/2008

HONG KONG, July 7 /PRNewswire/ -- OrbusNeich today announced that data presented recently at the 17th Annual Meeting of the Japanese Society of Interventional Cardiology demonstrate that the Genous Bio-engineered R stent has better outcomes when compared to drug-eluting stents.

Presented by Federico Piscione, M.D., the study's principal investigator and a professor with the Federico II University of Naples's Division of Cardiology, Department of Clinical Medicine and Cardiovascular Sciences, the data were generated following a study that involved 257 consecutive high-risk patients who underwent percutaneous coronary intervention with either the Genous stent or a TAXUS(R) and CYPHER(R) stent at the university's catheterization lab.

At 13 months clinical follow-up, the cumulative MACE rate for the Genous (GRS) group was 17.2% versus 26.4% for the combined TAXUS and CYPHER group (DES), a 35% reduction. For the MACE components, the rate of myocardial infarction (MI) was 4.5% for GRS versus 6.8% for DES, the re-percutaneous coronary intervention (Re-PCI) was 7.5% for GRS and 13.5% for DES, and the cardiac death rate was 4.5% for GRS versus 7.4% for DES. In addition, the rate for stent thrombosis was 0% for GRS versus 5.8% for DES.

"Our results suggest that the Genous Bio-engineered R stent is safe and effective in high-risk patients," said Piscione. "The results show a better long-term clinical outcome when compared with DES."

After PCI, patients who received GRS were prescribed dual-antiplatelet therapy for one month, and patients who received DES were prescribed the same therapy for 12 months. A complete clinical follow-up was obtained in 100% of GRS patients vs. 96% of DES patients.

Additionally, 22 consecutive patients requiring "life saving", undeferrable major noncardiac surgery (NCS) or endovascular aortic repair (EVAR), underwent coronary angiography for clinical or instrumental signs of ischemia before NCS or EVAR and were treated with the Genous stent. Antiplatelet therapy was stopped five days prior to scheduled surgery in all patients, with an average antiplatelet therapy duration of 12.5 days. After NCS, thienopyridine administration was not restarted and 100 mg per day of ASA was the only cardiac antiplatelet therapy at discharge. MACE, including in-hospital cardiac death, MI, stent thrombosis, surgical bleeding complications, need for revascularization and 30 day after surgery clinical follow- up, were evaluated.

The results of the study indicated an optimal acute procedural result in all patients. The 22 patients included in the study underwent uneventful NCS 10 to 22 days after coronary stent deployment. MACE rates were 0% at in-hospital follow-up and at one month follow-up.

"The Genous stent may offer a new, important and feasible therapeutic strategy for patients needing to undergo life-saving or undeferrable major noncardiac surgery early after coronary stent deployment," said Piscione.

Unlike drug-eluting stents, Genous, which is coated with an antibody, captures a patient's EPCs to accelerate the natural healing process. EPCs circulate in the bloodstream and are involved in the repair of blood vessels. When attracted to the surface of Genous, EPCs rapidly form an endothelial layer over the stent that provides protection against thrombus and minimizes restenosis.

OrbusNeich designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. The company's product portfolio includes the Genous(TM) Bio-engineered R stent(TM), an antibody-coated device that is the first-ever stent to capture a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process following placement. Other products are stents, balloons and guiding catheters marketed under the names of Blazer(TM), R stent(TM), Scoreflex(TM), Sapphire(TM), Avita(TM), Avita HP(TM), SafeCut(TM), Lumina(TM) and Saffron.

As a global company, OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; Tokyo; and Shenzhen, China. OrbusNeich, which has provided cardiology devices to physicians through its predecessor companies since 1979, today supplies products to interventional cardiologists in more than 60 countries. For more information, visit http://www.OrbusNeich.com .


'/>"/>
SOURCE OrbusNeich
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
3. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
6. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
9. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , Dec. 5, 2016  Balloon catheter is ... which is inserted into the femoral artery in the ... arm to treat constricted blood vessels. These products are ... to atherosclerosis – deposition of lipid substances in the ... catheter market is projected to expand at a CAGR ...
(Date:12/5/2016)... , Dec. 5, 2016  Zimmer Biomet Holdings, Inc. ... that, pursuant to its previously-announced cash tender offers ... the table below (collectively, the "Notes"), approximately $2.6 billion ... tendered and not validly withdrawn on or prior ... time, today, December 5, 2016 (the "Early ...
(Date:12/5/2016)... LONDON , Dec. 5 2016 ... 2022 Summary GlobalData,s new report, "United ... provides key market data on the United Kingdom ... in millions of US dollars, volume (in units) ... Optical Coherence Tomography (OCT), Retinal Ultrasound Imaging Systems, ...
Breaking Medicine Technology:
(Date:12/5/2016)... ... 2016 , ... What: Shriners Hospitals for Children, with the help of Dimension ... using a video monitor and web-enabled camera. Santa visits with children through Dimension Data’s ... Christmas Wonderland, which is where the video connection to the North Pole will stream. ...
(Date:12/5/2016)... ... December 05, 2016 , ... "FCPX Overlay Glare is a tool ... effect without heavy rendering or complicated compositing," said Christina Austin - CEO of Pixel ... an organic spectrum of lights that simulates the look of a glare. Just ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... Surgery, is excited to announce the arrival of the newest Sciton laser in ... the ability to use tunable non-ablative and ablative wavelengths for exceptional results. Outperforming ...
(Date:12/5/2016)... ... December 05, 2016 , ... The Avamere Family of Companies ... Avamere Transitional Care of Puget Sound ; located at 630 S Pearl Street, ... provide patients recovering from illness or injury with intensive skilled nursing and rehabilitation ...
(Date:12/5/2016)... ... ... For many years, Andrew G. Zubinas has accumulated over 130 ... the Lithuanian language and its poetry inspired him in writing “ Forest ... all aspects of a living, breathing forest where nothing ever stays the same. His ...
Breaking Medicine News(10 mins):